{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T14:50:39Z","timestamp":1758811839305},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1007\/s11886-009-0059-z","type":"journal-article","created":{"date-parts":[[2009,11,28]],"date-time":"2009-11-28T06:01:24Z","timestamp":1259388084000},"page":"407-413","source":"Crossref","is-referenced-by-count":27,"title":["Characterization and treatment of resistant hypertension"],"prefix":"10.1007","volume":"11","author":[{"given":"Roberto","family":"Pisoni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa I.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Calhoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,11,29]]},"reference":[{"key":"59_CR1","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1161\/CIRCULATIONAHA.108.189141","volume":"117","author":"D.A. Calhoun","year":"2008","unstructured":"Calhoun DA, Jones D, Textor S, et al.: Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association professional education committee of the council for high blood pressure research. Circulation 2008, 117:e510\u2013e526.","journal-title":"Circulation"},{"key":"59_CR2","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","volume":"42","author":"A.V. Chobanian","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR, et al.: Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003, 42:1206\u20131252.","journal-title":"Hypertension"},{"key":"59_CR3","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1524-6175.2002.02045.x","volume":"4","author":"W.C. Cushman","year":"2002","unstructured":"Cushman WC, Ford CE, Cutler JA, et al.: Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 2002, 4:393\u2013404.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"59_CR4","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1001\/jama.290.21.2805","volume":"290","author":"C.J. Pepine","year":"2003","unstructured":"Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al.: A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The international verapamil-trandolapril study (INVEST): a randomized controlled trial. JAMA 2003, 290:2805\u20132816.","journal-title":"JAMA"},{"key":"59_CR5","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1097\/00004872-200111000-00018","volume":"19","author":"C. Cuspidi","year":"2001","unstructured":"Cuspidi C, Macca G, Sampieri L, et al.: High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens 2001, 19:2063\u20132070.","journal-title":"J Hypertens"},{"key":"59_CR6","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","volume":"360","author":"S. Lewington","year":"2002","unstructured":"Lewington S, Clarke R, Qizilbash N, et al.: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903\u20131913.","journal-title":"Lancet"},{"key":"59_CR7","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1001\/archinte.168.21.2340","volume":"168","author":"G.F. Salles","year":"2008","unstructured":"Salles GF, Cardoso CR, Muxfeldt ES: Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Arch Intern Med 2008, 168:2340\u20132346.","journal-title":"Arch Intern Med"},{"key":"59_CR8","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1001\/archinternmed.2009.68","volume":"169","author":"E.S. Muxfeldt","year":"2009","unstructured":"Muxfeldt ES, Cardoso CR, Salles GF: Prognostic value of nocturnal blood pressure reduction in resistant hypertension. Arch Intern Med 2009, 169:874\u2013880.","journal-title":"Arch Intern Med"},{"key":"59_CR9","doi-asserted-by":"crossref","unstructured":"Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg [no authors listed]. JAMA 1967, 202:1028\u20131034.","DOI":"10.1001\/jama.1967.03130240070013"},{"key":"59_CR10","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.HYP.36.4.594","volume":"36","author":"D.M. Lloyd-Jones","year":"2000","unstructured":"Lloyd-Jones DM, Evans JC, Larson MG, et al.: Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension 2000, 36:594\u2013599.","journal-title":"Hypertension"},{"key":"59_CR11","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1001\/archinte.168.11.1159","volume":"168","author":"K.K. Gaddam","year":"2008","unstructured":"Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, et al.: Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008, 168:1159\u20131164.","journal-title":"Arch Intern Med"},{"key":"59_CR12","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s11906-008-0092-0","volume":"10","author":"C.C. Gonzaga","year":"2008","unstructured":"Gonzaga CC, Calhoun DA: Resistant hypertension and hyperaldosteronism. Curr Hypertens Rep 2008, 10:496\u2013503.","journal-title":"Curr Hypertens Rep"},{"key":"59_CR13","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1056\/NEJMcp041698","volume":"355","author":"M. Moser","year":"2006","unstructured":"Moser M, Setaro JF: Clinical practice. Resistant or difficult-to-control hypertension. N Engl J Med 2006, 355:385\u2013392.","journal-title":"N Engl J Med"},{"key":"59_CR14","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.amjhyper.2005.05.014","volume":"18","author":"S.D. Pierdomenico","year":"2005","unstructured":"Pierdomenico SD, Lapenna D, Bucci A, et al.: Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens 2005, 18:1422\u20131428.","journal-title":"Am J Hypertens"},{"key":"59_CR15","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1161\/01.HYP.0000035858.04434.03","volume":"40","author":"G.M. Singer","year":"2002","unstructured":"Singer GM, Izhar M, Black HR: Goal-oriented hypertension management: translating clinical trials to practice. Hypertension 2002, 40:464\u2013469.","journal-title":"Hypertension"},{"key":"59_CR16","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1001\/archinte.162.4.413","volume":"162","author":"S.A. Oliveria","year":"2002","unstructured":"Oliveria SA, Lapuerta P, McCarthy BD, et al.: Physicianrelated barriers to the effective management of uncontrolled hypertension. Arch Intern Med 2002, 162:413\u2013420.","journal-title":"Arch Intern Med"},{"key":"59_CR17","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.amjhyper.2004.08.031","volume":"18","author":"N. Boudville","year":"2005","unstructured":"Boudville N, Ward S, Benaroia M, House AA: Increased sodium intake correlates with greater use of antihypertensive agents by subjects with chronic kidney disease. Am J Hypertens 2005, 18:1300\u20131305.","journal-title":"Am J Hypertens"},{"key":"59_CR18","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0021-9681(74)90079-4","volume":"27","author":"F.W. Ashley Jr","year":"1974","unstructured":"Ashley FW Jr, Kannel WB: Relation of weight change to changes in atherogenic traits: the Framingham study. J Chronic Dis 1974, 27:103\u2013114.","journal-title":"J Chronic Dis"},{"key":"59_CR19","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1161\/01.HYP.17.4.565","volume":"17","author":"M. Modan","year":"1991","unstructured":"Modan M, Almog S, Fuchs Z, et al.: Obesity, glucose intolerance, hyperinsulinemia, and response to antihypertensive drugs. Hypertension 1991, 17:565\u2013573.","journal-title":"Hypertension"},{"key":"59_CR20","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1161\/01.HYP.0000079505.25750.11","volume":"42","author":"L. Mosso","year":"2003","unstructured":"Mosso L, Carvajal C, Gonzalez A, et al.: Primary aldosteronism and hypertensive disease. Hypertension 2003, 42:161\u2013165.","journal-title":"Hypertension"},{"key":"59_CR21","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1161\/01.HYP.0000040261.30455.B6","volume":"40","author":"D.A. Calhoun","year":"2002","unstructured":"Calhoun DA, Nishizaka MK, Zaman MA, et al.: Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002, 40:892\u2013896.","journal-title":"Hypertension"},{"key":"59_CR22","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/sj.ki.5000177","volume":"69","author":"V.M. Campese","year":"2006","unstructured":"Campese VM, Mitra N, Sandee D: Hypertension in renal parenchymal disease: why is it so resistant to treatment? Kidney Int 2006, 69:967\u2013973.","journal-title":"Kidney Int"},{"key":"59_CR23","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","volume":"139","author":"A.S. Levey","year":"2003","unstructured":"Levey AS, Coresh J, Balk E, et al.: National kidney foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med 2003, 139:137\u2013147.","journal-title":"Ann Intern Med"},{"key":"59_CR24","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0140-6736(05)67814-2","volume":"366","author":"J.P. Casas","year":"2005","unstructured":"Casas JP, Chua W, Loukogeorgakis S, et al.: Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005, 366:2026\u20132033.","journal-title":"Lancet"},{"key":"59_CR25","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/00004872-200018060-00004","volume":"18","author":"L. Grote","year":"2000","unstructured":"Grote L, Hedner J, Peter JH: Sleep-related breathing disorder is an independent risk factor for uncontrolled hypertension. J Hypertens 2000, 18:679\u2013685.","journal-title":"J Hypertens"},{"key":"59_CR26","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/sleep\/24.6.721","volume":"24","author":"P. Lavie","year":"2001","unstructured":"Lavie P, Hoffstein V: Sleep apnea syndrome: a possible contributing factor to resistant. Sleep 2001, 24:721\u2013725.","journal-title":"Sleep"},{"key":"59_CR27","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1097\/00004872-200112000-00022","volume":"19","author":"A.G. Logan","year":"2001","unstructured":"Logan AG, Perlikowski SM, Mente A, et al.: High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens 2001, 19:2271\u20132277.","journal-title":"J Hypertens"},{"key":"59_CR28","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1378\/chest.06-1442","volume":"131","author":"M.N. Pratt-Ubunama","year":"2007","unstructured":"Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, et al.: Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest 2007, 131:453\u2013459.","journal-title":"Chest"},{"key":"59_CR29","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1136\/thx.2003.015875","volume":"59","author":"G.V. Robinson","year":"2004","unstructured":"Robinson GV, Stradling JR, Davies RJ: Sleep. 6: Obstructive sleep apnoea\/hypopnoea syndrome and hypertension. Thorax 2004, 59:1089\u20131094.","journal-title":"Thorax"},{"key":"59_CR30","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(05)67139-5","volume":"366","author":"J.W. Lenders","year":"2005","unstructured":"Lenders JW, Eisenhofer G, Mannelli M, Pacak K: Phaeochromocytoma. Lancet 2005, 366:665\u2013675.","journal-title":"Lancet"},{"key":"59_CR31","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.amjhyper.2004.11.021","volume":"18","author":"J.P. Garg","year":"2005","unstructured":"Garg JP, Elliott WJ, Folker A, et al.: Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens 2005, 18:619\u2013626.","journal-title":"Am J Hypertens"},{"key":"59_CR32","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1161\/HYPERTENSIONAHA.107.096933","volume":"51","author":"R.C. Hermida","year":"2008","unstructured":"Hermida RC, Ayala DE, Fernandez JR, Calvo C: Chronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertension. Hypertension 2008, 51:69\u201376.","journal-title":"Hypertension"},{"key":"59_CR33","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","volume":"359","author":"K. Jamerson","year":"2008","unstructured":"Jamerson K, Weber MA, Bakris GL, et al.: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008, 359:2417\u20132428.","journal-title":"N Engl J Med"},{"key":"59_CR34","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/01.HYP.0000203309.07140.d3","volume":"47","author":"M.E. Ernst","year":"2006","unstructured":"Ernst ME, Carter BL, Goerdt CJ, et al.: Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006, 47:352\u2013358.","journal-title":"Hypertension"},{"key":"59_CR35","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","author":"ALLHAT OfficersCoordinators for the ALLHAT Collaborative Research Group. The AntihypertensiveLipid-Lowering Treatment to Prevent Heart Attack Trial","year":"2002","unstructured":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipidlowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002, 288:2981\u20132997.","journal-title":"JAMA"},{"key":"59_CR36","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","volume":"16","author":"M.K. Nishizaka","year":"2003","unstructured":"Nishizaka MK, Zaman MA, Calhoun DA: Efficacy of lowdose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003, 16:925\u2013930.","journal-title":"Am J Hypertens"},{"key":"59_CR37","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1097\/00004872-200411000-00026","volume":"22","author":"I.K. Eide","year":"2004","unstructured":"Eide IK, Torjesen PA, Drolsum A, et al.: Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004, 22:2217\u20132226.","journal-title":"J Hypertens"},{"key":"59_CR38","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/clpt.1990.210","volume":"48","author":"R.R. Townsend","year":"1990","unstructured":"Townsend RR, DiPette DJ, Goodman R, et al.: Combined alpha\/beta-blockade versus beta 1-selective blockade in essential hypertension in black and white patients. Clin Pharmacol Ther 1990, 48:665\u2013675.","journal-title":"Clin Pharmacol Ther"},{"key":"59_CR39","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0300-8932(09)70158-7","volume":"62","author":"E. Rodilla","year":"2009","unstructured":"Rodilla E, Costa JA, Perez-Lahiguera F, et al.: Spironolactone and doxazosin treatment in patients with resistant hypertension. Rev Esp Cardiol 2009, 62:158\u2013166.","journal-title":"Rev Esp Cardiol"},{"key":"59_CR40","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/01.hjh.0000163159.22116.ab","volume":"23","author":"G.S. Stergiou","year":"2005","unstructured":"Stergiou GS, Makris T, Papavasiliou M, et al.: Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy. J Hypertens 2005, 23:883\u2013889.","journal-title":"J Hypertens"},{"key":"59_CR41","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","volume":"358","author":"S. Yusuf","year":"2008","unstructured":"Yusuf S, Teo KK, Pogue J, et al.: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358:1547\u20131559.","journal-title":"N Engl J Med"},{"key":"59_CR42","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","volume":"372","author":"J.F. Mann","year":"2008","unstructured":"Mann JF, Schmieder RE, McQueen M, et al.: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372:547\u2013553.","journal-title":"Lancet"},{"key":"59_CR43","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0140-6736(07)61124-6","volume":"370","author":"S. Oparil","year":"2007","unstructured":"Oparil S, Yarows SA, Patel S, et al.: Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007, 370:221\u2013229.","journal-title":"Lancet"},{"key":"59_CR44","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S0140-6736(09)60566-3","volume":"373","author":"H. Krum","year":"2009","unstructured":"Krum H, Schlaich M, Whitbourn R, et al.: Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009, 373:1275\u20131281.","journal-title":"Lancet"},{"key":"59_CR45","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.jvs.2006.08.024","volume":"44","author":"K.A. Illig","year":"2006","unstructured":"Illig KA, Levy M, Sanchez L, et al.: An implantable carotid sinus stimulator for drug-resistant hypertension: Surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial. J Vasc Surg 2006, 44:1213\u20131218.","journal-title":"J Vasc Surg"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-009-0059-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-009-0059-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-009-0059-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T23:56:12Z","timestamp":1559433372000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-009-0059-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["59"],"URL":"https:\/\/doi.org\/10.1007\/s11886-009-0059-z","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}